Stock PODD INSULET CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Insulet Corporation

Equities

PODD

US45784P1012

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-19 pm EDT 		5-day change 1st Jan Change
166.2 USD +0.92% Intraday chart for Insulet Corporation -5.12% -23.38%
Mar. 20 US Equity Markets Close Higher Wednesday as Fed Holds Rates Steady MT
Mar. 20 Insulet Names Ana Maria Chadwick Finance Chief MT

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

  • Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 61% by 2026.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • For the past twelve months, EPS forecast has been revised upwards.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
  • The group usually releases upbeat results with huge surprise rates.

Weaknesses

  • With an expected P/E ratio at 56.46 and 44.12 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • Based on current prices, the company has particularly high valuation levels.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The company is highly valued given the cash flows generated by its activity.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
INSULET CORPORATION Stock Insulet Corporation
-23.38% 11.53B
B-
ABBOTT LABORATORIES Stock Abbott Laboratories
-2.53% 183B
C+
MEDTRONIC PLC Stock Medtronic plc
-3.52% 105B
C
DEXCOM, INC. Stock DexCom, Inc.
+5.33% 51.77B
B-
CENCORA, INC. Stock Cencora, Inc.
+16.43% 47.29B
B-
HOYA CORPORATION Stock Hoya Corporation
-1.73% 40.2B
B+
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
+5.66% 27.62B
A-
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
-2.01% 25.51B
B
TERUMO CORPORATION Stock Terumo Corporation
+9.84% 24.73B
A-
ZIMMER BIOMET HOLDINGS, INC. Stock Zimmer Biomet Holdings, Inc.
-1.87% 24.52B
B
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. PODD Stock
  4. Ratings Insulet Corporation